Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis.
Amoxapine, a dibenzoxazepine antidepressant, has been suggested to have atypical antipsychotic properties. We tested it to control psychosis in three patients with Parkinson's disease (PD). Two patients had significant improvement in hallucinations, whereas the third could not tolerate the drug for a sufficient period. All three patients experienced a decline in motor function; two also had concomitant reduction in dyskinesias. Therefore, although we found some support for amoxapine having antipsychotic properties, this drug seems to carry a risk of worsening motor function in patients with PD.
Sa
D S
DS
Movement Disorders Unit, Division of Neurology, Toronto Western Hospital, ON, Canada.
Kapur
S
S
Lang
A E
AE
D000368:Aged; D000657:Amoxapine / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019957:Motor Skills Disorders / Q000139:chemically induced*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D011605:Psychoses, Substance-Induced / Q000188:drug therapy* / Q000523:psychology
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D000657:Amoxapine